Evidence map›Paper›PMID 42817804›Full record

ArticleCNS neuroscience & therapeutics2026

METTL3 Increases Temozolomide Resistance in MGMT-Negative Glioblastoma by Enhancing CBX5 mRNA Stability in an m

Hui Deng, Ruoyu Chen, Daohong Qu, Cifu Qu, Jia Shi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hui DengDepartment of Neurosurgery, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Ruoyu ChenDepartment of Neurosurgery, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Daohong QuDepartment of Neurosurgery, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Cifu QuCentre of Clinical Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jia ShiDepartment of Neurosurgery, The Third Affiliated Hospital of Soochow University, Changzhou, China.ORCID https://orcid.org/0009-0004-1712-818X

Funding

Changzhou Municipal Science and Technology Bureau CJ20245009
6 · The paper itself

Abstract

aimsWe examined whether chromobox protein 5 (CBX5) contributes to temozolomide (TMZ) resistance in O

methodsPublic datasets, clinical specimens, MGMT-negative cells, and subcutaneous xenografts were examined using functional, mechanistic, and rescue assays.

resultsIn the CGGA693 cohort of the Chinese Glioma Genome Atlas, higher CBX5 expression remained associated with shorter survival after multivariable adjustment (hazard ratio 1.178, 95% confidence interval 1.050-1.322; p = 0.005). CBX5 depletion increased TMZ sensitivity, apoptosis, and DNA damage, reduced ATM phosphorylation and RAD51 abundance, and restricted TMZ-treated xenograft growth; overexpression produced reciprocal effects in vitro. METTL3 depletion reduced CBX5 expression, mRNA stability, m

conclusionMETTL3-dependent m

Indexed as

Antineoplastic Agents, AlkylatingBrain NeoplasmsDrug Resistance, NeoplasmGlioblastomaMethyltransferasesRNA-Binding ProteinsTemozolomideAdenosineAnimalsCell Line, TumorChromobox Protein Homolog 5DNA Modification MethylasesDNA Repair EnzymesHumansMiceMice, NudeAdenosineAntineoplastic Agents, AlkylatingCBX5 protein, humanChromobox Protein Homolog 5DNA Modification MethylasesDNA Repair EnzymesIGF2BP2 protein, humanMethyltransferasesMETTL3 protein, humanMGMT protein, humanN-methyladenosineRNA-Binding ProteinsRNA, MessengerTemozolomideTumor Suppressor ProteinsCBX5glioblastomaIGF2BP2METTL3N6‐methyladenosinetemozolomide resistance

Identifiers

PMID42817804
PMCPMC13628293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.